嚢胞性線維症の2030年までの市場予測：薬剤クラス別、治療法別、投与経路別、流通チャネル別、地域別の世界分析

Stratistics MRCによると、嚢胞性線維症の世界市場は2023年に114億9,000万米ドルを占め、予測期間中にCAGR 22.4％で成長し、2030年には473億米ドルに達すると予測されています。

嚢胞性線維症（CF）として知られる遺伝性疾患の原因は遺伝子変異です。特定の体液のタンパク質分泌は遺伝子によって制御されています。これは体内の様々な器官に影響を及ぼし、粘液や汗を濃くする傾向があります。さらに、この病気は電解質輸送系を変化させ、細胞によるナトリウムと水分の吸収をもたらし、汗と粘液の分泌を担当する腺に問題を引き起こします。

嚢胞性線維症患者登録によると、米国では現在3万人以上がこの病気に苦しんでおり、世界中で約7万人がこの病気に苦しんでいると推定されています。

個別化医療と遺伝子検査

個々の患者のCFTR遺伝子変異を正確に特定する能力は、遺伝子配列決定技術と遺伝子検査の進歩によって可能となっています。この個別化アプローチの助けにより、医療専門家は、各患者の特定の遺伝子プロファイルに応じて治療計画をカスタマイズし、最適な薬剤を提供することができます。さらに、個別化医療を重視することで、患者の満足度と治療効果を高めることができるため、市場はさらに活性化しています。

高額な医療費

嚢胞性線維症の治療費は非常に高額で、特にCFTRモジュレーターの場合、年間数十万米ドルに上ることもあります。このような過大な出費は、保険会社や医療システムを圧迫し、すべての患者にアクセスを提供することを困難にする可能性があります。さらに、これらの治療薬の長期的な購入可能性に関する懸念も、費用によってもたらされ、市場拡大に影響を及ぼす可能性があります。

薬剤送達システムの改善

インテリジェント吸入器や効果的なネブライザーなど、ドラッグデリバリーの進歩により、治療管理は向上しています。しかし、これらの実用的かつ効率的なドラッグデリバリー戦略は、患者が治療の恩恵を十分に受けられることを保証するため、患者の経験を向上させ、アドヒアランスを促進し、ひいては市場拡大の一助となります。

複雑な治療計画

嚢胞性線維症の治療計画には、薬剤、治療法、生活習慣の改善が複雑に絡み合っていることがよくあります。この複雑さは患者を圧倒し、治療へのアドヒアランスを低下させる可能性があります。さらに、コンプライアンス違反の結果、医療費用が増加し、増悪が頻発する可能性があります。

COVID-19の影響：

COVID-19の大流行は、患者の治療、臨床試験、医療システムに大きな混乱を引き起こし、嚢胞性線維症市場にも影響を与えました。パンデミックは医療資源に負担をかけ、新しい治療法の導入を遅らせ、研究開発を先送りしました。嚢胞性線維症と診断された人々は、ハイリスク集団とみなされ、健康上のリスクが増大し、必要な医療へのアクセスが制限されることも多かっています。さらに、パンデミックの経済的影響は、医療システムと患者の経済的負担を増大させ、嚢胞性線維症治療の費用と利用しやすさに影響を与える可能性があっています。

嚢胞性線維症の膜貫通伝導調節因子モジュレーターセグメントが予測期間中最大となる見込み

膜貫通伝導調節因子モジュレーターは、この複雑で課題も多い遺伝性疾患の治療にパラダイムシフトをもたらすと期待されており、その変革的インパクトから嚢胞性線維症市場で最大のシェアを占めると予想されています。さらに、嚢胞性線維症の治療は、Trikaftaのような膜貫通伝導調節因子モジュレーターによって一変しました。これらの薬剤は、嚢胞性線維症の原因となる根本的な遺伝子欠損に対処することにより、粘液クリアランスと塩化物輸送を改善します。特定の遺伝子変異を持つ多くの患者にとって、膜貫通伝導調節因子モジュレーターは肺機能を大幅に改善し、増悪を抑え、QOLを向上させる。

予測期間中、CAGRが最も高くなると予想される吸入セグメント

嚢胞性線維症市場では、吸入療法分野が最もCAGRが高いです。吸入療法は、標的を絞った効果的な方法で薬剤を肺に直接投与するため、近年ますます普及しています。吸入器は、嚢胞性線維症の症状のコントロールを補助する薬剤を送達するために、これらの治療で一般的に使用されています。さらに、吸入セグメントの著しい成長は、吸入技術の進歩、吸入治療の利点に関する意識の高まり、特に吸入投与を目的とした新規薬剤の創出など、様々な要因に起因しています。

最大のシェアを持つ地域

嚢胞性線維症は北米が最大の市場シェアを占めています。これは、同地域の市場優位性を支えるいくつかの要因によるものです。まず、北米では一般市民も医療関係者も嚢胞性線維症に対する認識が高く、医療のインフラが整備されています。そのため、患者の早期診断・治療が容易で、患者層が拡大し、嚢胞性線維症治療薬市場が拡大します。さらに、この地域には、最先端の嚢胞性線維症治療法の開発に積極的に取り組んでいる製薬会社や研究施設が数多くあります。最先端の医療機器が利用可能であることや、有利な診療報酬制度も、この地域の市場シェアを押し上げています。

CAGRが最も高い地域：

アジア太平洋は、嚢胞性線維症市場において最も高いCAGRが見込まれています。この地域では嚢胞性線維症の患者数が増加しており、医療を含む多くの産業で急成長が見られます。この地域の急成長は、嚢胞性線維症に対する社会的認知の拡大、医療インフラの充実、医療費の上昇など、多くの要因によるものです。さらに、中国やインドなどの各国政府は、医療の低価格化と利用しやすさの向上を目指したプログラムを実施しており、診断と治療により良い選択肢を提供することで、嚢胞性線維症患者に恩恵をもたらすでしょう。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場参入企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データ鉱業
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• イントロダクション
• 促進要因
• 抑制要因
• 機会
• 脅威
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の嚢胞性線維症市場：薬剤クラス別

• イントロダクション
• 膵臓酵素サプリメント
• 粘液溶解性
• 気管支拡大薬
• 抗生物質
• 嚢胞性線維症の膜貫通伝導調節因子モジュレーター
• その他の薬剤クラス

第6章 世界の嚢胞性線維症市場：治療法別

• イントロダクション
• 薬剤
• 装置

第7章 世界の嚢胞性線維症市場：投与経路別

• イントロダクション
• 経口
• 吸入

第8章 世界の嚢胞性線維症市場：流通チャネル別

• イントロダクション
• 病院
• ドラッグストア
• 小売薬局
• その他の流通チャネル

第9章 世界の嚢胞性線維症市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東およびアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東およびアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• Pharmaxis Ltd
• Gilead Sciences, Inc.
• Teva Pharmaceuticals
• Genentech Inc
• AbbVie Inc.
• Mylan N.V
• Viatris Inc.
• Novartis AG
• Allergan PLC
• Pfizer Inc
• Nestle Health Science
• Hoffmann-La Roche AG
• BayerAG
• Vertex Pharmaceuticals Incorporated
• AstraZeneca
• Chiesi Farmaceutici SpA
• Horizon Therapeutic Plc.

List of Tables

• Table 1 Global Cystic Fibrosis Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 3 Global Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 4 Global Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 5 Global Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 6 Global Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 7 Global Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 8 Global Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 9 Global Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 10 Global Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 11 Global Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 12 Global Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 13 Global Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 14 Global Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 15 Global Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 16 Global Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 17 Global Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 18 Global Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 19 Global Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 20 North America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 21 North America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 22 North America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 23 North America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 24 North America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 25 North America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 26 North America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 27 North America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 28 North America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 29 North America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 30 North America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 31 North America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 32 North America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 33 North America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 34 North America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 35 North America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 36 North America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 37 North America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 38 North America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 39 Europe Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 40 Europe Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 41 Europe Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 42 Europe Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 43 Europe Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 44 Europe Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 45 Europe Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 46 Europe Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 47 Europe Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 48 Europe Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 49 Europe Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 50 Europe Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 51 Europe Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 52 Europe Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 53 Europe Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 54 Europe Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 55 Europe Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 56 Europe Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 57 Europe Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 58 Asia Pacific Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 59 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 60 Asia Pacific Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 61 Asia Pacific Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 62 Asia Pacific Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 63 Asia Pacific Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 64 Asia Pacific Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 65 Asia Pacific Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 66 Asia Pacific Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 67 Asia Pacific Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 68 Asia Pacific Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 69 Asia Pacific Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 70 Asia Pacific Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 71 Asia Pacific Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 72 Asia Pacific Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 73 Asia Pacific Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 74 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 75 Asia Pacific Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 76 Asia Pacific Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 77 South America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 78 South America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 79 South America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 80 South America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 81 South America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 82 South America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 83 South America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 84 South America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 85 South America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 86 South America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 87 South America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 88 South America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 89 South America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 90 South America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 91 South America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 92 South America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 93 South America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 94 South America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 95 South America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 96 Middle East & Africa Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
• Table 97 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 98 Middle East & Africa Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
• Table 99 Middle East & Africa Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
• Table 100 Middle East & Africa Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
• Table 101 Middle East & Africa Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 102 Middle East & Africa Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
• Table 103 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
• Table 104 Middle East & Africa Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
• Table 105 Middle East & Africa Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
• Table 106 Middle East & Africa Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
• Table 107 Middle East & Africa Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 108 Middle East & Africa Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
• Table 109 Middle East & Africa Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
• Table 110 Middle East & Africa Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 111 Middle East & Africa Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
• Table 112 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
• Table 113 Middle East & Africa Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 114 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

According to Stratistics MRC, the Global Cystic Fibrosis Market is accounted for $11.49 billion in 2023 and is expected to reach $47.30 billion by 2030 growing at a CAGR of 22.4% during the forecast period. A genetic mutation is the cause of the inherited disease known as cystic fibrosis (CF). Certain bodily liquids' protein secretion is regulated by genes. This affects different organs in the body, which tends to thicken mucus and sweat. Moreover, this illness modifies the electrolyte transport system, which results in the absorption of sodium and water by cells and causes issues with the glands responsible for producing sweat and mucus.

According to the Cystic Fibrosis Patient Registry, it is estimated that more than 30,000 people are currently suffering from this condition in the U.S. and it is estimated that about 70,000 people are suffering from it across the globe.

Market Dynamics:

Driver:

Personalized medicine and genetic testing

The ability to precisely identify CFTR gene mutations in individual patients has been made possible by advances in genetic sequencing technologies and genetic testing. With the help of this individualized approach, medical professionals can customize treatment plans and offer the best medications depending on each patient's particular genetic profile. Additionally, the market is further propelled by the emphasis on personalized medicine, which raises patient satisfaction and treatment effectiveness.

Restraint:

Expensive medical care

The cost of treating cystic fibrosis can be extremely high, sometimes amounting to hundreds of thousands of dollars per year, particularly for CFTR modulators. These excessive expenses may put pressure on insurers and healthcare systems, making it more difficult to provide access to all patients. Furthermore, concerns about these treatments' long-term affordability are also brought up by cost, which could have an impact on market expansion.

Opportunity:

Improvements in medication delivery systems

Treatment administration has been enhanced by advances in drug delivery, such as intelligent inhalers and effective nebulizers. However, since they guarantee that patients get the full benefit of their treatments, these practical and efficient drug delivery strategies improve patient experience, promote adherence, and subsequently aid in market expansion.

Threat:

Complex therapy plans

Treatment plans for cystic fibrosis frequently entail a complicated mix of drugs, therapies, and lifestyle modifications. This complexity has the potential to overwhelm patients and result in poor adherence to treatment, which will ultimately compromise the efficacy of therapies and patient outcomes. Moreover, healthcare expenses may rise, and exacerbations may occur more frequently as a result of noncompliance.

COVID-19 Impact:

The COVID-19 pandemic caused major disruptions in patient care, clinical trials, and healthcare systems, which in turn affected the cystic fibrosis market. The pandemic put a strain on healthcare resources, delayed the introduction of new treatments, and postponed research and development. Individuals diagnosed with cystic fibrosis, who were regarded as a high-risk population, experienced increased health risks and frequently had limited access to necessary medical care. Furthermore, the pandemic's economic effects put more strain on healthcare systems and patients' finances, which might have an impact on the cost and accessibility of cystic fibrosis treatments.

The Cystic Fibrosis Transmembrane Conductance Regulator Modulators segment is expected to be the largest during the forecast period

CFTR modulators are expected to hold the largest share in the cystic fibrosis market due to their transformative impact, which is expected to represent a paradigm shift in the treatment of this complex and challenging genetic disease. Moreover, treatment for cystic fibrosis has been transformed by CFTR modulators such as Trikafta. These medications improve mucus clearance and chloride transport by addressing the underlying genetic defect that causes cystic fibrosis. For many patients with particular genetic mutations, CFTR modulators greatly improve lung function, lower exacerbations, and improve quality of life.

The Inhaled segment is expected to have the highest CAGR during the forecast period

The inhaled segment of the cystic fibrosis market has the highest CAGR. Because inhaled therapies deliver medication directly to the lungs in a targeted and effective manner, they have become increasingly popular in recent years. Inhalers are commonly used in these therapies to deliver medications that assist in controlling the symptoms of cystic fibrosis. Additionally, the significant growth of the inhaled segment can be attributed to various factors, such as the progression of inhalation technology, heightened consciousness regarding the advantages of inhalation treatments, and the creation of novel medications especially intended for inhalation administration.

Region with largest share:

North America holds the largest market share for cystic fibrosis. This is explained by a number of factors that support the region's market dominance. First off, both the general public and medical professionals in North America are highly aware of cystic fibrosis, and the continent has a well-established healthcare infrastructure. This makes it easier to diagnose and treat patients early, which expands the patient pool and raises the market for cystic fibrosis treatments. Furthermore, there are many pharmaceutical companies and research facilities in the area that are actively working to develop cutting-edge cystic fibrosis treatments. The availability of cutting-edge medical equipment and advantageous reimbursement practices also boost the market share of the area.

Region with highest CAGR:

The Asia-Pacific region is anticipated to have the highest CAGR in the cystic fibrosis market. This region is seeing a rise in the number of cases of cystic fibrosis and is seeing rapid growth in a number of industries, including healthcare. The region's rapid growth is attributed to a number of factors, including expanding public awareness of cystic fibrosis, enhancing healthcare infrastructure, and rising healthcare costs. Moreover, governments in nations such as China and India are implementing programs aimed at improving healthcare affordability and accessibility, which will benefit patients with cystic fibrosis by providing better options for diagnosis and treatment.

Key players in the market

Some of the key players in Cystic Fibrosis market include: Pharmaxis Ltd , Gilead Sciences, Inc., Teva Pharmaceuticals, Genentech Inc , AbbVie Inc., Mylan N.V, Viatris Inc., Novartis AG, Allergan PLC, Pfizer Inc, Nestle Health Science, Hoffmann-La Roche AG , BayerAG, Vertex Pharmaceuticals Incorporated, AstraZeneca , Chiesi Farmaceutici SpA and Horizon Therapeutic Plc.

Key Developments:

In October 2023, Teva Pharmaceuticals and Sanofi have announced an agreement to jointly develop and commercialise a treatment for inflammatory bowel disease, with the deal potentially worth up to $1.5bn.The candidate, Teva's TEV'574, is an anti-TL1A therapy currently being evaluated in phase 2b clinical trials as a treatment for ulcerative colitis and Crohn's disease, the two main types of inflammatory bowel disease.

In October 2023, Viatris Inc., a global healthcare company, today announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered into definitive agreements to divest its Women's Healthcare business, its Active Pharmaceutical Ingredients (API) business in India and commercialization rights in certain non-core markets that were acquired as part of the Upjohn Transaction.

In September 2023, PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical today announced a new multi-target collaboration and license agreement with U.S.-based Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope ("peptide-RI") drug conjugates.

Drug Classes Covered:

• Pancreatic Enzyme Supplements
• Mucolytic
• Bronchodilators
• Antibiotics
• Cystic Fibrosis Transmembrane Conductance Regulator Modulators
• Other Drug Classes

Treatment Methods Covered:

• Medication
• Devices

Route of Administrations Covered:

• Oral
• Inhaled

Distribution Channels Covered:

• Hospital
• Drug Stores
• Retail Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cystic Fibrosis Market, By Drug Class

• 5.1 Introduction
• 5.2 Pancreatic Enzyme Supplements
• 5.3 Mucolytic
• 5.4 Bronchodilators
• 5.5 Antibiotics
• 5.6 Cystic Fibrosis Transmembrane Conductance Regulator Modulators
• 5.7 Other Drug Classes

6 Global Cystic Fibrosis Market, By Treatment Method

• 6.1 Introduction
• 6.2 Medication
• 6.3 Devices

7 Global Cystic Fibrosis Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Inhaled

8 Global Cystic Fibrosis Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital
• 8.3 Drug Stores
• 8.4 Retail Pharmacies
• 8.5 Other Distribution Channels

9 Global Cystic Fibrosis Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Pharmaxis Ltd
• 11.2 Gilead Sciences, Inc.
• 11.3 Teva Pharmaceuticals
• 11.4 Genentech Inc
• 11.5 AbbVie Inc.
• 11.6 Mylan N.V
• 11.7 Viatris Inc.
• 11.8 Novartis AG
• 11.9 Allergan PLC
• 11.10 Pfizer Inc
• 11.11 Nestle Health Science
• 11.12 Hoffmann-La Roche AG
• 11.13 BayerAG
• 11.14 Vertex Pharmaceuticals Incorporated
• 11.15 AstraZeneca
• 11.16 Chiesi Farmaceutici SpA
• 11.17 Horizon Therapeutic Plc.